A team of scientists from the University of California, San Francisco (UCSF) has overturned a long-held understanding of how two key hormones, estrogen and progesterone, act in cells. Their findings, published in the journal *Cell*, could lead to new treatments for a variety of diseases, including cancer and infertility.
For decades, it was believed that estrogen and progesterone worked by binding to receptors in the nucleus of cells, where they turned on or off genes. However, the UCSF team found that these hormones can also work by binding to receptors on the surface of cells, where they activate different signaling pathways.
"This is a major paradigm shift in our understanding of how these hormones work," said senior author Dr. Kevan Shokat. "It opens up new possibilities for developing drugs that target these hormones in different ways."
Estrogen and progesterone are two of the most important hormones in the female body. They are responsible for regulating the menstrual cycle, pregnancy, and menopause. They also play a role in bone health, heart health, and mood.
The UCSF team's findings could lead to new treatments for a variety of diseases that are caused by imbalances in estrogen and progesterone levels, such as cancer, infertility, and osteoporosis.
"We are excited to explore the potential therapeutic applications of this new understanding of how estrogen and progesterone work," said Shokat. "We believe that our findings could lead to new treatments that are more effective and have fewer side effects."
The UCSF team used a variety of techniques to study how estrogen and progesterone work in cells. They found that these hormones can bind to two different receptors: the nuclear receptor and the membrane receptor.
The nuclear receptor is located in the nucleus of cells, where it turns on or off genes. The membrane receptor is located on the surface of cells, where it activates different signaling pathways.
The team found that estrogen and progesterone can both bind to the nuclear receptor and the membrane receptor. However, the effects of these hormones are different depending on which receptor they bind to.
When estrogen binds to the nuclear receptor, it turns on genes that are responsible for cell growth and proliferation. When estrogen binds to the membrane receptor, it activates signaling pathways that are responsible for cell differentiation and survival.
Similarly, when progesterone binds to the nuclear receptor, it turns on genes that are responsible for preparing the uterus for pregnancy. When progesterone binds to the membrane receptor, it activates signaling pathways that are responsible for maintaining pregnancy.
The team's findings suggest that the balance between nuclear and membrane signaling is critical for the normal function of estrogen and progesterone. Imbalances in this balance can lead to a variety of diseases, such as cancer, infertility, and osteoporosis.
The UCSF team's findings could lead to new treatments for a variety of diseases that are caused by imbalances in estrogen and progesterone levels.
For example, in patients with breast cancer, estrogen can bind to the membrane receptor and activate signaling pathways that promote cell growth and proliferation. This could lead to the development of new drugs that target the membrane receptor and block the growth of breast cancer cells.
In patients with infertility, progesterone can bind to the membrane receptor and activate signaling pathways that are responsible for maintaining pregnancy. This could lead to the development of new drugs that target the membrane receptor and help women to conceive.
In patients with osteoporosis, estrogen can bind to the nuclear receptor and turn on genes that are responsible for bone formation. This could lead to the development of new drugs that target the nuclear receptor and help to prevent osteoporosis.
The UCSF team is currently exploring the potential therapeutic applications of their findings. They believe that their findings could lead to new treatments that are more effective and have fewer side effects.
